^
Association details:
| Biomarker: | CDKN2A mutation |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Palbociclib (P) in patients (Pts) with pancreatic cancer (PC) and gallbladder or bile duct cancer (GBC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Published date:
05/16/2018
Excerpt:
Palbociclib (P) in patients (Pts) with...gallbladder or bile duct cancer (GBC) with CDKN2A alterations…No ORs or SD at 16 wks were observed in the PC or GBC pts and both cohorts were therefore closed....Monotherapy with P does not have clinical activity in PC or GBC pts with CDKN2A loss or mutation.
DOI:
10.1200/JCO.2018.36.15_suppl.2532
Trial ID:
